Lithium

Mood stabilizer, Antimanic

Lithium

Lithobid (extended-release); Eskalith (discontinued in US); Carbolith (Canada); Priadel (UK); Camcolit (UK)

Lithium is a mood stabilizer used primarily in the treatment and prevention of bipolar disorder. A simple monovalent cation (the third element on the periodic table), lithium has a narrower therapeutic index than almost any other medicine in common psychiatric use: the serum concentration required for benefit is close to the concentration that produces toxicity, necessitating regular blood level monitoring as a standing condition of its use. Despite this constraint, lithium has the longest evidence base of any medicine in bipolar disorder, the most robust evidence for suicide prevention of any psychiatric medicine, and a neuroprotective profile (preservation of gray matter volume, BDNF upregulation) that no other mood stabilizer has matched in controlled imaging studies. It has a history unlike any other psychiatric medicine: it was in use as a mineral water component at spas centuries before its mechanism was even speculated at, removed from consumer products when its toxicity was recognized, and rediscovered by an Australian psychiatrist experimenting on guinea pigs in 1949. The gap between empirical discovery and mechanistic understanding is wider for lithium than for almost any other medicine in the formulary. That gap has never fully closed.

History

Lithium (symbol Li, atomic number 3) is the lightest solid element and the lightest metal. It was identified in 1817 by Swedish chemist Johan August Arfwedson while analyzing petalite ore; its name derives from the Greek lithos (stone). Lithium naturally occurs in trace amounts in many mineral waters, and "lithia water" (mineral water with elevated lithium content) was commercially popular throughout the 19th century as a health tonic. Producers marketed it for gout, kidney stones, and a variety of nervous complaints, a claim that would later prove to have a pharmacological basis more interesting than the marketers intended.

In 1883, Alfred Baring Garrod (who had earlier identified uric acid's role in gout) proposed lithium for the treatment of "brain gout," a now-abandoned diagnostic category that grouped mania and other agitated states with metabolic disease. Lithium bromide was used in the 19th and early 20th centuries as a sedative, contributing to the empirical record without mechanistic understanding.

In the 1940s, lithium chloride was marketed as a salt substitute for patients on sodium-restricted diets. Physicians treating cardiac patients with this substitute reported toxicity and several deaths. The FDA moved to restrict lithium from consumer products in 1949, creating an ironic historical footnote: the same year lithium was withdrawn from over-the-counter use, John Cade was rediscovering its psychiatric utility.

John Frederick Joseph Cade, an Australian psychiatrist at the Bundoora Repatriation Mental Hospital in Victoria, was investigating the hypothesis that mania resulted from excess uric acid in the blood. To test urinary urate in guinea pigs, he needed to dissolve uric acid (poorly water-soluble); he used lithium urate, the most soluble lithium salt available. He observed that the guinea pigs became unexpectedly calm rather than showing expected toxicity signs. Curious, he administered lithium carbonate to other guinea pigs and found the same sedative effect. He then tried it in human patients with mania.

In September 1949, Cade published a series of 10 manic patients who responded dramatically to lithium carbonate, along with cases of schizophrenia (no clear benefit) and melancholia (modest benefit). The paper, published in the Medical Journal of Australia, is now recognized as one of the most important papers in the history of psychiatry. Cade himself was a careful experimenter: he documented that the effect was specific to mania, he first tested the doses on himself, and he noted the narrow therapeutic window with appropriate caution.

The clinical adoption of lithium was slow. In the United States, the 1949 deaths from lithium salt substitutes had left regulatory caution, and Cade's paper attracted limited attention. The Danish psychiatrist Mogens Schou, working with Juel-Nielsen and others, conducted the first randomized controlled trial of lithium in mania in 1954 and published subsequent work throughout the 1960s establishing its prophylactic efficacy. Schou also had a personal stake: his brother had severe bipolar disorder and responded to lithium.

The FDA approved lithium carbonate for acute mania in 1970, making the United States one of the last Western countries to adopt it. Europe and Australia had been using it clinically for a decade. The FDA subsequently approved the maintenance indication in bipolar disorder.

In the US popular imagination, lithium's cultural moment arrived partly through its association with creative and intellectual figures who were open about their diagnoses. Kay Redfield Jamison's memoir "An Unquiet Mind" (1995), in which the psychiatrist and bipolar disorder expert describes her own mania, depression, and ambivalent relationship with lithium, brought its clinical and experiential dimensions to a wide audience. The tension Jamison described between lithium's life-stabilizing effects and the patients' experiences of mood restriction resonates across decades of clinical literature on adherence.

One historical footnote: the original formulation of 7-Up, introduced in 1929 as "Bib-Label Lithiated Lemon-Lime Soda," contained lithium citrate as an ingredient. The lithium was removed in 1948 amid the concern about lithium toxicity, though the brand retained its name.

Experience

👥 No personal reports yet

⚕ No clinical reports yet

Log in to add your own experience.

Problems

FDA-approved indications:

• Acute mania: Treatment of manic episodes in patients with bipolar I disorder. Lithium reduces the severity and duration of manic episodes. Because its onset requires days to weeks, it is typically combined with a neuroleptic or benzodiazepine in the acute phase.
• Maintenance treatment of bipolar disorder: Prophylactic reduction of the frequency and severity of manic and depressive episodes in bipolar I disorder. This is the indication with the strongest long-term evidence base.

Off-label uses (not FDA-approved):

• Bipolar II disorder: Evidence for lithium in bipolar II (characterized by hypomania and depression rather than full mania) is limited but includes some trial data supporting mood stabilization.^{[citation needed]}
• Bipolar depression: Lithium shows antidepressant properties in bipolar depression, though evidence is more modest than for mania and maintenance. Quetiapine and lurasidone have more recent controlled trial data for bipolar depression.
• Augmentation of antidepressants in unipolar depression: One of the most evidence-supported augmentation strategies for treatment-resistant unipolar depression. Meta-analyses find significant benefit over placebo, though newer augmentation strategies (atypical neuroleptics) have displaced it in some guidelines due to convenience and tolerability.
• Suicide prevention: Lithium has the most robust evidence base of any medicine for reducing suicidal behavior across mood disorders. A 2013 Cochrane-affiliated meta-analysis by Cipriani et al. found that lithium reduced the risk of all-cause mortality and suicide compared to placebo and compared to other mood stabilizers in bipolar disorder and recurrent depression. The mechanism is debated; possibilities include serotonergic effects, anti-aggressive properties, and circadian stabilization, independent of mood stabilization per se.
• Cluster headache prophylaxis: Evidence from case series and small controlled trials supports lithium as a second-line prophylactic for chronic cluster headache. The mechanism may involve its effects on circadian rhythmicity.^{[citation needed]}
• Neutropenia: Lithium stimulates granulopoiesis and is used in some clinical contexts to raise white blood cell counts, particularly neutropenia associated with chemotherapy or clozapine therapy.^{[citation needed]}
• Dementia prevention: Epidemiological data from regions with higher lithium concentrations in drinking water suggest an inverse association with dementia rates. Early-phase trials of very low-dose lithium for Alzheimer's prevention are underway; this remains investigational.^{[citation needed]}

+ Add a problem

Titration strategies

Lithium dosing is guided entirely by serum level monitoring. Dose-to-level relationships vary widely between individuals based on renal function, sodium intake, hydration status, and concurrent medicines. No dose is "correct" outside of its corresponding serum level.

Acute mania: Target serum lithium level 0.8-1.2 mEq/L. Begin at 300 mg two to three times daily with food and titrate upward every 3-5 days with serum level checks (12-hour trough). Most adults require 900-1,800 mg/day divided. A neuroleptic should be added for acute behavioral control while lithium reaches therapeutic levels.

Maintenance (prophylaxis): Target serum level 0.6-0.8 mEq/L. Lower targets (0.4-0.6 mEq/L) may be appropriate in elderly patients or in those who tolerate higher levels poorly; higher targets (0.8-1.0 mEq/L) are sometimes used in patients with more severe or treatment-resistant illness. Once stable, serum levels can be monitored every 3-6 months in conjunction with renal and thyroid function tests.

Extended-release formulations (Lithobid): May allow twice-daily dosing and reduce peak-trough fluctuations that contribute to gastrointestinal side effects and tremor. Bioequivalence with immediate-release at the same total daily dose; serum level targets unchanged.

Renal impairment: Lithium is exclusively renally excreted; dose must be substantially reduced in proportion to reduced creatinine clearance. Mild impairment (GFR 30-60 mL/min): reduce dose by 25-50%. Severe impairment (GFR <30 mL/min): use with extreme caution and very close monitoring, if at all. Hemodialysis patients can receive lithium but require post-dialysis dosing protocols due to dialyzability.

Elderly patients: Renal clearance of lithium declines with age in parallel with declining GFR. Lower doses and lower target serum levels (0.4-0.6 mEq/L) are appropriate. The elderly are at higher risk of toxicity even within the nominal therapeutic range due to reduced volume of distribution and age-related sensitivity to neurological effects.

Pediatric: Not FDA-approved in children under 12. Some evidence supports use in pediatric bipolar disorder; off-label use occurs. Dosing is weight-based; serum level targets are similar to adults.

+ Add a titration strategy

Effects

Mood stabilization. Lithium's primary effect is reduction of manic episodes, with secondary prophylactic effects on depressive episodes. In clinical experience, many patients describe a "floor" that prevents the ascent into hypomania or mania; the prophylactic effect on depression is present but generally less robust than the antimanic effect. The medicine does not eliminate all episodes; it reduces their frequency, severity, and duration.

Anti-suicidal effect. Lithium has the most replicated and robust evidence base of any medicine for reducing suicidal behavior. This effect appears to be at least partially independent of mood stabilization per se: lithium reduces suicidality beyond what would be predicted from its antimanic effects alone. Proposed mechanisms include serotonergic modulation (increasing impulse control and reducing aggression) and circadian stabilization. The clinical implication is that lithium should be considered specifically when suicide risk is a prominent concern in a mood-disordered patient, even in cases where other medicines might be equivalent for mood stabilization.

Neuroprotection. Neuroimaging studies consistently find that patients with bipolar disorder on chronic lithium therapy have greater gray matter volume in prefrontal and limbic regions compared to bipolar patients on other medicines and, in some studies, compared to healthy controls. Lithium increases brain-derived neurotrophic factor (BDNF) and promotes hippocampal neurogenesis in animal models. Whether this translates to measurable cognitive protection in humans over long follow-up is an active area of investigation.^{[citation needed]}

Experiential perspective. Lithium occupies an unusual place in patients' subjective experience of their medicines. Many patients attribute it with stabilizing their lives in ways that feel foundational; others describe what Kay Redfield Jamison, among others, has documented: a reduction in emotional range that feels like a trade-off rather than a purely beneficial change. The creative and intellectual "highs" of hypomania, which may be valued by the patient even when recognized as pathological, are dampened along with frank mania. Cognitive side effects ("foggy thinking," word-finding difficulty, memory complaints) are among the most common reasons cited for nonadherence.

The subjective experience of lithium is shaped significantly by serum levels: patients near the upper end of the therapeutic range report more side effects than those in the lower half, and some patients with previously poor tolerance achieve acceptable tolerability when levels are held at 0.6-0.8 rather than 0.8-1.0 mEq/L. Level-targeting is one of the most productive interventions for lithium nonadherence.

Cognitive effects. Lithium produces measurable effects on cognitive performance in some studies: psychomotor slowing, reduced verbal memory, and diminished word fluency at higher levels. These effects are dose-related. At lower serum levels (0.4-0.6 mEq/L), cognitive effects may be minimal and may be offset by the cognitive improvements that come with mood stabilization in patients who were previously cycling.^{[citation needed]}Common adverse effects:

• Fine hand tremor: The most common neurological side effect, occurring in 10-30% of patients. Often manageable with dose reduction, level reduction, or the addition of propranolol (40-120 mg/day). Coarse tremor (different from fine tremor) is a sign of toxicity, not a chronic side effect, and requires urgent evaluation.
• Polyuria and polydipsia: Nephrogenic diabetes insipidus (NDI) occurs in up to 40% of long-term users. Lithium impairs the kidney's ability to concentrate urine by reducing collecting duct responsiveness to antidiuretic hormone (ADH/vasopressin). Mild polyuria is common; some patients produce 3-4 liters of urine per day. If symptomatic, amiloride (5-10 mg/day, a potassium-sparing diuretic) can reduce urine volume without substantially affecting lithium levels and is preferred over thiazide diuretics for this indication.
• Weight gain: Variable in magnitude; median gain approximately 4-7 kg in long-term studies. Mechanism is not fully established; increased thirst driving high-calorie beverage intake and insulin effects are proposed contributors.
• Gastrointestinal: Nausea, diarrhea, and abdominal discomfort are common, particularly at initiation and with immediate-release formulations. Taking lithium with food or switching to extended-release formulations substantially reduces GI side effects for most patients.
• Cognitive effects: Word-finding difficulty, slowed processing, and memory complaints are reported by a substantial minority of patients; see Effects section above.

Endocrine:

• Hypothyroidism: The most clinically important chronic endocrine effect. Lithium inhibits thyroid hormone synthesis and release. Subclinical hypothyroidism (elevated TSH, normal free T4) occurs in approximately 20-40% of long-term users; overt hypothyroidism requiring levothyroxine in approximately 10-20%, more commonly in women and in those with pre-existing thyroid antibodies. Hypothyroidism can worsen depression and attenuate the mood-stabilizing response; TSH monitoring every 6 months is a standing requirement of lithium management. Levothyroxine supplementation allows lithium continuation in most cases.
• Hyperparathyroidism: Lithium raises serum calcium and parathyroid hormone (PTH) levels, and long-term use is associated with increased risk of primary hyperparathyroidism (PHPT). The mechanism involves lithium's effect on the calcium-sensing receptor in parathyroid cells, which raises the set-point for calcium-mediated PTH suppression. Symptomatic or severe hypercalcemia may require parathyroidectomy; in some cases it resolves after lithium discontinuation.^{[citation needed]}

Renal:

• Chronic tubulointerstitial nephropathy: Long-term lithium use (decades) is associated with progressive interstitial fibrosis and tubular atrophy in some patients. The risk appears to be duration-dependent and level-dependent. A significant minority of long-term lithium users (estimates vary from 1% to 3% after 20+ years) develop chronic kidney disease reaching stage 3 or below (GFR <60 mL/min). Whether lithium should be continued in the setting of declining GFR requires individualized benefit-risk assessment: the benefits of lithium (including anti-suicidal effects) may outweigh the renal risk in patients with severe bipolar disorder who have not responded to alternatives.
• Nephrogenic diabetes insipidus (NDI): See above under polyuria. In most patients, NDI is reversible upon lithium discontinuation; however, prolonged severe NDI can lead to irreversible structural changes in the collecting duct.

Cardiovascular:

• ECG changes: Flattening or inversion of T-waves is common and benign; a known lithium effect that does not indicate cardiac pathology. Sinus node dysfunction and sinoatrial block are rare but reported, particularly in older patients and at higher serum levels.^{[citation needed]}
• Blood pressure: No consistent hypertensive effect; mild hypotension is sometimes reported.

Dermatologic:

• Acne, psoriasis exacerbation, hair thinning, and folliculitis are reported. Psoriasis exacerbation can be severe and may necessitate lithium discontinuation if unresponsive to dermatologic treatment.^{[citation needed]}

+ Add an effect

Pharmacokinetics

Absorption

Lithium is completely absorbed from the gastrointestinal tract; the oral bioavailability of lithium carbonate is essentially 100%. Immediate-release formulations produce a peak serum concentration within 1-2 hours after ingestion. Extended-release formulations produce a lower, flatter peak at 3-6 hours, which reduces the amplitude of peak-trough fluctuations. Food does not substantially affect total absorption but may delay peak concentration slightly and reduce gastrointestinal discomfort. Lithium citrate oral solution is absorbed as rapidly as immediate-release tablets.

Distribution

Lithium distributes throughout total body water. It does not bind to plasma proteins (0% protein binding). The apparent volume of distribution is approximately 0.7-1.0 L/kg, reflecting distribution throughout total body water including intracellular fluid. Lithium crosses the blood-brain barrier; brain concentrations at steady state are approximately 40-60% of serum levels. It also crosses the placenta (reaching fetal concentrations near maternal levels) and is secreted into breast milk (approximately 40-50% of maternal serum levels).

Lithium enters cells slowly via sodium channels and sodium-lithium countertransport. The slow equilibration between intracellular and extracellular compartments explains two clinically important phenomena: (1) steady-state tissue concentrations are reached over 5-7 days even when serum levels stabilize earlier, and (2) after hemodialysis removes lithium from blood, redistribution from tissues produces a rebound rise in serum levels (the "post-dialysis rebound"), requiring repeat dialysis or close level monitoring after each dialysis session.

Metabolism

Lithium is not metabolized. It is excreted unchanged. There are no hepatic cytochrome P450 interactions because lithium does not interact with the CYP system. This makes lithium unusual among major psychiatric medicines in having no pharmacokinetic interactions with other medicines via metabolism; its interactions are pharmacodynamic or renal.

Elimination

Lithium is eliminated exclusively by the kidneys. Renal excretion involves glomerular filtration followed by approximately 80% reabsorption in the proximal tubule, a process that occurs in competition with sodium reabsorption. The proximal tubule reabsorbs lithium and sodium in proportion to their concentrations and to sodium avidity. This has the critical clinical consequence: any state of sodium depletion (dietary sodium restriction, vomiting, diarrhea, sweating, diuretic use) increases proximal tubular reabsorption of both sodium and lithium, raising serum lithium levels and precipitating toxicity. Patients must be counseled that dehydration and sodium loss can cause lithium toxicity even at stable lithium doses.

The elimination half-life is approximately 18-24 hours after a single acute dose and may extend to 36-48 hours at steady state due to tissue equilibration. Renal clearance of lithium is proportional to creatinine clearance; any condition that reduces GFR will proportionally reduce lithium clearance and raise serum levels. Age-related decline in GFR is a major reason elderly patients require lower doses for equivalent serum levels.

Pharmacodynamics

Lithium's pharmacodynamic profile is characterized by the absence of receptor specificity: it is not an agonist or antagonist at any known receptor and does not inhibit monoamine reuptake. Its effects derive from interference with intracellular signaling enzymes (IMPase, GSK-3beta, adenylyl cyclase) and modulation of ion transport, producing downstream changes in multiple neurotransmitter systems simultaneously. See Mechanism section above for detailed description.

The defining pharmacodynamic fact about lithium is its narrow therapeutic index: therapeutic effects occur at serum levels of 0.6-1.2 mEq/L; toxicity begins to appear at 1.5 mEq/L; severe toxicity at 2.0 mEq/L and above. This roughly two-fold ratio between the therapeutic level and the onset of serious toxicity is among the smallest of any medicine in routine psychiatric use. Clinical management of lithium is therefore inseparable from serum level monitoring.

Unlike most receptor-targeted medicines, lithium does not have a clearly defined dose-response relationship that saturates at a specific ceiling. The benefit of higher vs. lower serum levels within the therapeutic range varies by indication and patient, and the risk of toxicity rises continuously with increasing levels. This produces the practical therapeutic target of finding the lowest level that controls mood episodes for each patient.

Interactions

Lithium's interactions are almost entirely renal rather than metabolic. Any medicine or condition that reduces renal sodium clearance or GFR will raise lithium levels.

NSAIDs (ibuprofen, naproxen, indomethacin, celecoxib, and most others): Prostaglandins modulate renal blood flow and tubular sodium handling; NSAID inhibition of prostaglandin synthesis reduces lithium excretion by 25-30% and can precipitate toxicity within days. Even low-dose over-the-counter NSAIDs are clinically significant. Aspirin at analgesic doses is a lesser concern (different mechanism); acetaminophen is considered safe.

ACE inhibitors and angiotensin receptor blockers (ARBs): Can substantially raise lithium levels by reducing GFR (through efferent arteriolar dilation) and by increasing proximal tubular reabsorption via the renin-angiotensin-aldosterone axis. Lithium toxicity can develop within days of starting an ACE inhibitor or ARB in a patient on stable lithium. Close monitoring of lithium levels and renal function is required when these medicines are combined. Dose reduction is often necessary.^{[citation needed]}

Thiazide diuretics (hydrochlorothiazide, chlorthalidone): Thiazides reduce distal tubular sodium reabsorption, causing the body to compensate by increasing proximal tubular sodium (and lithium) reabsorption. This raises serum lithium levels by 25-50%. Combination requires dose reduction and close monitoring. Paradoxically, thiazides are sometimes used therapeutically to reduce urine output in lithium-induced nephrogenic diabetes insipidus (at lower doses than typically used for hypertension), with careful level monitoring.

Loop diuretics (furosemide, bumetanide): Less problematic than thiazides at typical clinical doses because they act on the loop of Henle rather than the proximal tubule. However, if loop diuretics produce significant sodium and volume depletion, lithium levels can rise. Monitor levels when initiating.

Amiloride: Generally considered safe for use with lithium (unlike thiazides) and preferred for treating lithium-induced polyuria and NDI. May minimally affect lithium levels; monitoring is still prudent.

Carbamazepine: The combination can produce neurotoxicity (ataxia, confusion, tremor) even when serum levels of both medicines are within their individual therapeutic ranges. The mechanism is pharmacodynamic, not pharmacokinetic. Use with caution and monitor for neurological symptoms.

Metronidazole: Inhibits renal lithium clearance; can raise levels significantly. Avoid or reduce lithium dose and monitor closely.^{[citation needed]}

Theophylline and caffeine: Increase renal lithium clearance, reducing serum levels. Heavy caffeine use may produce sub-therapeutic levels; sudden caffeine cessation in a stabilized patient may raise lithium to toxic levels. Clinically relevant primarily for patients on high caffeine intake.^{[citation needed]}

Neuroleptics: The combination of lithium and high-potency neuroleptics (particularly haloperidol) was historically associated with case reports of severe neurotoxicity (irreversible brain damage, death). Subsequent review suggested these cases occurred predominantly at high lithium levels (often above therapeutic range) or in contexts of acute febrile illness. The interaction is pharmacodynamic and likely reflects additive neurotoxicity risk at high serum levels rather than a specific haloperidol-lithium reaction. The combination remains widely used in clinical practice with appropriate level monitoring.^{[citation needed]}

SSRIs and SNRIs: Combination increases serotonergic transmission; serotonin syndrome has been reported (though rarely). More practically, adding lithium to an antidepressant for augmentation is a well-established strategy; the risk of serotonin syndrome is real but low at therapeutic doses.^{[citation needed]}

Iodide-containing preparations: Synergistic hypothyroid effect when combined with lithium.^{[citation needed]}

Monitoring

Regular serum level monitoring is a standing requirement for lithium therapy, not an optional adjunct. Monitoring frequency:

• Initiation: Serum lithium level 5-7 days after each dose change (draw as a 12-hour trough, exactly 12 hours after the last dose). Renal function (BMP with creatinine/BUN) and thyroid function (TSH) at baseline.
• Stabilization: Once serum levels are stable in the target range, extend monitoring to every 1-3 months for the first year.
• Maintenance: Every 3-6 months for serum lithium level, renal function, and thyroid function in stable patients on long-term therapy.
• ECG: Baseline recommended, particularly in patients over 50 or with known cardiac disease.
• Weight: At each visit; weight gain is common and contributes to nonadherence.
• Urinalysis: Annually for proteinuria as a marker of renal disease progression in long-term users.
• Calcium/PTH: Consider periodic monitoring for hyperparathyroidism in long-term users (>5 years).

Clinicians should lower the monitoring threshold after any change in the patient's clinical state, concurrent medicines, or medical illness (particularly conditions affecting hydration, sodium intake, or renal function).

Patient counseling

Hydration and sodium. This is the single most important safety counseling point for lithium. Dehydration, excessive sweating (exercise, hot weather), dietary sodium restriction, vomiting, or diarrhea can all raise your lithium levels into the toxic range even if you have not changed your dose. Drink adequate water, maintain normal salt in your diet unless your cardiologist says otherwise, and call your prescriber if you develop any illness involving vomiting or diarrhea. If you are unsure whether to take your lithium during a GI illness, call before taking it rather than waiting.

Toxic symptom recognition. Know the early warning signs of lithium toxicity: coarse tremor of the hands (different from the fine tremor that may be a chronic side effect), unsteadiness, slurred speech, confusion, nausea with vomiting, or muscle twitching. These warrant urgent medical evaluation and a serum lithium level, not a "wait and see" approach. Going to an emergency room is appropriate.

Level monitoring. Your lithium blood level must be drawn exactly 12 hours after your last dose. Taking your dose, waiting less than 12 hours, or drawing blood at a random time gives a meaningless or misleading result. If you take lithium at 8 PM, your blood draw is at 8 AM; if at 10 PM, the draw is at 10 AM.

Medicines and lithium. Many common medicines raise lithium levels and can cause toxicity. This includes ibuprofen (Advil, Motrin), naproxen (Aleve), and all other non-aspirin anti-inflammatory pain medicines. Acetaminophen (Tylenol) is the safe alternative for pain and fever. Tell every prescriber and every pharmacist that you take lithium, and check for interactions before starting any new medicine including over-the-counter preparations.

Pregnancy. If you are pregnant or planning pregnancy, discuss your lithium with your prescriber before stopping it on your own. Abrupt discontinuation during pregnancy carries a high risk of manic relapse, which can itself harm you and the pregnancy. The risks of lithium in pregnancy are real but have been revised downward from older estimates; an informed discussion with your psychiatrist and obstetrician is the right approach, not unilateral discontinuation.

Thyroid and kidney. Regular blood tests check your thyroid and kidney function. These organs can be affected by long-term lithium use. Hypothyroidism (underactive thyroid) is treatable with thyroid hormone without stopping lithium. Kidney function needs periodic review; gradual decline in kidney function may occur after many years of use, and this is monitored so decisions can be made before serious damage occurs.

Relevant anecdote

Lithium occupies a strange position in the pharmacological imagination. It is simultaneously the oldest major treatment in psychopharmacology (the empirical tradition of lithia springs predates synthetic psychiatry by a century), the treatment with perhaps the most durable and replicable evidence base, and the treatment that most directly raises the question of what it means to stabilize someone's mood at the cost of their emotional range.

The literature on lithium and creativity is not merely anecdotal. A 1978 study by Schou found that among 24 lithium-treated artists and writers in Denmark, some reported that lithium had improved their output by allowing them to work consistently rather than in manic bursts; others reported reduced creative productivity. Jamison and others have documented the ambivalence in first-person terms: the person who writes brilliantly in hypomania and is, on lithium, capable of sustained work but perhaps not brilliance. This is not a side effect in the conventional sense; it is a direct consequence of the medicine's intended action.

The suicide prevention evidence is worth a closer look than it typically receives in summary form. Cipriani et al.'s 2013 BMJ meta-analysis pooled 48 randomized trials and found that lithium significantly reduced suicide deaths (OR 0.13, 95% CI 0.03-0.66) and the combined endpoint of completed suicide plus deliberate self-harm (OR 0.21, 95% CI 0.08-0.50) compared to placebo. Compared to active controls (anticonvulsants including valproate and carbamazepine), lithium showed similar efficacy for mood stabilization but superior efficacy for suicide prevention. The anti-suicidal effect is not trivially explained by better mood stabilization: studies controlling for mood episode rates still find lithium superior. The specific mechanism of lithium's anti-suicidal action is unknown; plausible candidates include its serotonergic effects on impulse control and its anti-aggressive properties.

There is a population-level corollary: epidemiological studies from multiple countries have found that municipalities with higher naturally occurring lithium concentrations in drinking water have lower rates of suicide mortality, even controlling for socioeconomic and demographic factors. These findings are observational and do not establish causation; they have also been challenged on methodological grounds. But they have provoked legitimate scientific interest in whether trace environmental lithium exposure may influence population suicide rates, and have generated ongoing research into very low-dose lithium supplementation.

The 1949 coincidence remains one of the great ironies in medicine's regulatory history: lithium was removed from consumer products (as a salt substitute) and simultaneously published as a breakthrough psychiatric treatment. The medicine that was being withdrawn from soft drinks and marketed salt substitutes was being discovered to prevent psychotic mania. This compression of the timeline was not noticed at the time; Cade's paper received almost no immediate attention in the United States, precisely because lithium had just been associated with toxicity and death.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary

Classes

Mood stabilizer, Antimanic

Common uses

• Bipolar I Disorder★★★★★★★★★★★★★★★—×
• Bipolar II Disorder★★★★★★★★★★★★★★★—×
• Bipolar Disorder★★★★★★★★★★★★★★★—×
• Treatment-resistant depression (augmentation)★★★★★★★★★★★★★★★—×
• Cluster headache★★★★★★★★★★★★★★★—×

+ 1 more use →

Pharmacy

Starting dose

300 mg orally two to three times daily, with food or milk to reduce gastrointestinal irritation. Extended-release formulations (Lithobid 450 mg) may be dosed twice daily. Titrate to serum lithium levels: target 0.8-1.2 mEq/L for acute mania, 0.6-0.8 mEq/L for maintenance.

Preparations

Lithium carbonate: immediate-release capsules (150 mg, 300 mg, 600 mg) and tablets (300 mg); extended-release tablets (300 mg, 450 mg). Lithium citrate: oral solution (8 mEq/5 mL, equivalent to 300 mg lithium carbonate per 5 mL) for patients unable to swallow tablets.

US FDA Max

No defined absolute maximum; dosing is guided by serum level monitoring. Levels above 1.5 mEq/L carry increasing toxicity risk. Levels consistently above 1.2 mEq/L are generally not maintained in clinical practice.

Pharmacology

Routes

Oral

Onset

Antimanic effects begin within 5-7 days of reaching therapeutic serum levels, with full response often requiring 2-3 weeks. For acute mania, a neuroleptic is typically added for rapid sedation while lithium takes effect.

Duration

Lithium is a long-term medicine; protective effects against mood episodes continue only with sustained administration. Prophylactic benefit against recurrence continues for years of maintenance use. Relapse risk is elevated in the months following discontinuation, particularly with abrupt cessation.

Half-life

Approximately 18-24 hours after acute administration; may extend to 36-48 hours with chronic dosing as tissue compartments equilibrate. Serum trough levels should be drawn 12 hours after the last dose for accurate interpretation.

Bioavailability

Oral bioavailability is essentially complete (near 100%) for lithium carbonate in solution and immediate-release tablets. Extended-release tablets have slightly delayed peak concentrations and somewhat lower peak levels, which reduces gastrointestinal side effects without substantially altering total absorption.

Pregnancy

Lithium crosses the placenta. Historically, it was associated with Ebstein's anomaly (a cardiac malformation affecting the tricuspid valve) based on the International Register of Lithium Babies, a voluntary registry with significant ascertainment bias. Later population-based cohort data substantially revised this risk downward: the absolute risk of Ebstein's anomaly in lithium-exposed pregnancies is approximately 1 in 1,000 to 1 in 2,000 (vs. 1 in 20,000 in the general population), a relative risk of approximately 1.5-2-fold rather than the 400-fold initially suggested. First-trimester exposure carries the highest cardiac teratogenicity risk. Neonatal toxicity (lithium toxicity syndrome: hypotonia, cyanosis, bradycardia) can occur in the newborn if maternal levels are in the high-therapeutic range at delivery; gradual dose reduction near term or close monitoring is recommended. Lithium passes into breast milk; breastfeeding is generally discouraged due to infant renal immaturity. The benefit-risk calculus in women with severe bipolar disorder is complex and individualized: discontinuation in pregnancy carries its own risks of manic relapse, which may itself harm the fetus and mother.

Legal status

Not a controlled substance in the United States, European Union, United Kingdom, Canada, or Australia. Prescription-only in all of these jurisdictions due to the narrow therapeutic index and the need for serum monitoring. No abuse potential has been identified.

Purported mechanism

Lithium's mechanism of action in bipolar disorder remains incompletely understood despite more than 70 years of clinical use, which is itself instructive: its therapeutic benefits were empirically established long before any molecular target was identified, and no single mechanism fully explains its clinical profile.

Inositol signaling. The inositol depletion hypothesis, proposed by Berridge in 1989, holds that lithium inhibits inositol monophosphatase (IMPase) and related phosphatases involved in the phosphatidylinositol (PI) signaling cascade. At therapeutic concentrations, lithium is an uncompetitive inhibitor of IMPase, reducing the recycling of free inositol from inositol monophosphate. Because inositol is a precursor for phosphatidylinositol bisphosphate (PIP2), the substrate for phospholipase C signaling, chronic lithium treatment may selectively dampen overactive PI signaling in neurons with the highest activity levels. This "activity-dependent" dampening could explain mood stabilization without global neurological suppression.^{[citation needed]} However, the hypothesis remains contested; direct evidence in human neural tissue is limited.

GSK-3beta inhibition. Lithium directly inhibits glycogen synthase kinase-3 beta (GSK-3beta) at therapeutic concentrations, an effect now considered one of its most clinically important molecular actions. GSK-3beta is a constitutively active serine/threonine kinase involved in a remarkable range of cellular processes: circadian rhythm regulation, neuronal apoptosis, synaptic plasticity, and the Wnt signaling pathway. GSK-3beta is also a downstream target of several neurotransmitter systems implicated in bipolar disorder, including dopaminergic and serotonergic signaling. Inhibition of GSK-3beta by lithium may account for its neuroprotective effects (increased BDNF, gray matter volume preservation in imaging studies) and for aspects of its circadian-stabilizing and mood-stabilizing properties.

Adenylyl cyclase and second messenger systems. Lithium inhibits adenylyl cyclase and reduces cyclic AMP (cAMP) production in response to receptor stimulation, attenuating signaling through the adenylate cyclase pathway. It also modulates protein kinase C (PKC), which is involved in neurotransmitter release and synaptic regulation. The consequence is a general dampening of amplified second messenger signaling rather than blockade of a specific receptor.^{[citation needed]}

Neurotransmitter effects. Lithium modulates serotonergic, dopaminergic, noradrenergic, and glutamatergic signaling, though it is not a receptor antagonist or reuptake inhibitor in the classical sense. Chronic lithium treatment increases serotonin synthesis and release in some brain regions, which may contribute to its antidepressant and anti-suicidal effects. It reduces dopaminergic supersensitivity, potentially accounting for its antimanic properties. Glutamate regulation, including effects on NMDA receptor signaling, has been proposed as relevant to its neuroprotective effects.^{[citation needed]}

Circadian rhythm. Lithium lengthens the circadian period and inhibits GSK-3beta, which phosphorylates and degrades circadian clock proteins (Period, Cryptochrome). The resulting stabilization of circadian rhythms aligns with the circadian disruption seen in bipolar disorder and may be a primary mechanism of mood stabilization independent of classic neurotransmitter effects.^{[citation needed]}

The net picture: lithium acts through multiple simultaneously engaged mechanisms, none of which alone is sufficient to explain its clinical effects. This polypharmacy-within-a-molecule is consistent with the clinical observation that no other mood stabilizer fully replicates lithium's profile, particularly its unique anti-suicidal properties.